Drug Profile
Research programme: inflammatory disease-targeted antibodies - Peptimmune
Alternative Names: DEEP-AbLatest Information Update: 29 Aug 2011
Price :
$50
*
At a glance
- Originator Peptimmune
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Inflammation
Most Recent Events
- 22 Mar 2011 Suspended - Preclinical for Inflammation in USA (Parenteral)
- 19 Jul 2010 Preclinical trials in Inflammation in USA (Parenteral)